Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.17 USD
+0.14 (1.07%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $13.17 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value F Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 2,346.08 | 2,048.48 | 3,536.01 | 407.47 |
Depreciation/Amortization & Depletion | NA | 4,916.56 | 5,190.04 | 5,260.91 | 5,369.57 |
Net Change from Assets/Liabilities | NA | -843.91 | 877.58 | 2,592.34 | 870.98 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 812.23 | 1,879.55 | -1,886.51 | -486.30 |
Net Cash From Operating Activities | NA | 7,230.96 | 9,995.64 | 9,502.75 | 6,161.72 |
Property & Equipment | NA | -1,033.74 | -1,080.79 | -608.68 | -1,053.44 |
Acquisition/ Disposition of Subsidiaries | NA | 58.89 | -191.14 | 4,985.65 | 4,201.24 |
Investments | NA | 89.56 | 76.36 | 582.88 | 385.03 |
Other Investing Activities | NA | -3,607.26 | -567.76 | -1,260.66 | -845.33 |
Net Cash from Investing Activities | NA | -4,492.56 | -1,763.31 | 3,699.18 | 2,687.50 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -199.27 | -690.03 | -20.13 | -34.38 |
Issuance (Repayment) of Debt | NA | -2,084.36 | -4,990.95 | -4,438.60 | -1,884.78 |
Increase (Decrease) Short-Term Debt | NA | -25.17 | -353.29 | -1,770.14 | -3,507.25 |
Payment of Dividends & Other Distributions | NA | -2,067.68 | -2,524.62 | -2,663.56 | -2,599.75 |
Other Financing Activities | NA | -871.22 | -966.47 | -1,338.11 | -1,221.80 |
Net Cash from Financing Activities | NA | -5,247.70 | -9,525.36 | -10,230.53 | -9,247.96 |
Effect of Exchange Rate Changes | NA | 169.67 | 255.95 | 117.51 | -200.25 |
Net Change In Cash & Equivalents | NA | -2,339.62 | -1,037.09 | 3,088.92 | -598.99 |
Cash at Beginning of Period | NA | 6,287.74 | 8,599.38 | 5,993.57 | 6,465.04 |
Cash at End of Period | NA | 3,948.12 | 7,562.29 | 9,082.49 | 5,866.05 |
Diluted Net EPS | NA | 0.75 | 0.65 | 1.12 | 0.13 |
Fiscal Year End for Takeda Pharmaceutical Co falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 1,000.90 | 285.91 | 652.66 | 2,346.08 |
Depreciation/Amortization & Depletion | NA | 3,680.55 | 2,443.96 | 1,251.96 | 4,916.56 |
Net Change from Assets/Liabilities | NA | -2,144.58 | -1,030.56 | -1,595.69 | -843.91 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 439.88 | 310.71 | 365.58 | 812.23 |
Net Cash From Operating Activities | NA | 2,976.74 | 2,010.01 | 674.52 | 7,230.96 |
Property & Equipment | NA | -831.50 | -520.72 | -335.41 | -1,033.74 |
Acquisition/ Disposition of Subsidiaries | NA | 2.48 | 2.52 | 2.72 | 58.89 |
Investments | NA | -24.72 | -11.27 | -0.96 | 89.56 |
Other Investing Activities | NA | -1,882.42 | -1,727.59 | -1,612.03 | -3,607.26 |
Net Cash from Investing Activities | NA | -2,736.17 | -2,257.05 | -1,945.67 | -4,492.56 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -15.82 | -16.05 | -16.98 | -199.27 |
Issuance (Repayment) of Debt | NA | -1,501.56 | -1,008.03 | -0.64 | -2,084.36 |
Increase (Decrease) Short-Term Debt | NA | 1,608.92 | 609.87 | 726.01 | -25.17 |
Payment of Dividends & Other Distributions | NA | -1,890.82 | -964.70 | -954.45 | -2,067.68 |
Other Financing Activities | NA | -214.83 | 9.72 | -175.73 | -871.22 |
Net Cash from Financing Activities | NA | -2,014.11 | -1,369.19 | -421.78 | -5,247.70 |
Effect of Exchange Rate Changes | NA | 106.38 | 129.44 | 107.74 | 169.67 |
Net Change In Cash & Equivalents | NA | -1,667.16 | -1,486.81 | -1,585.20 | -2,339.62 |
Cash at Beginning of Period | NA | 3,628.00 | 3,681.36 | 3,894.77 | 6,287.74 |
Cash at End of Period | NA | 1,960.84 | 2,194.55 | 2,309.57 | 3,948.12 |
Diluted Net EPS | NA | 0.23 | -0.11 | 0.21 | 0.08 |